Skip to main content

Quest Patient Service Centers will be closed on Thursday, November 26th and will close at 12:00 PM on Friday, November 27th in observance of Thanksgiving and to give our frontline team time to recharge. Don’t let the holiday interrupt your care. Plan your visit today.

Hide

Blood-based biomarkers: A new window into neurological disease

Michael K. Racke, MD, Senior Medical Director for Neurology at Quest Diagnostics

When I began my career in neurology, we had relatively few ways to look beneath the symptoms of neurological disease, and even fewer proven therapies for many neurological conditions. My fellowship focused on multiple sclerosis (MS) at a time when there were no approved disease-modifying therapies. We relied heavily on the neurological examination, clinical history, imaging, and a limited number of laboratory tests.

Today as the Senior Medical Director for Neurology at Quest Diagnostics with more than three decades of experience in academia and clinical practice in the field of neurology and neuroimmunology, I marvel at how our understanding of disease biology has changed in recent years. Today, there are more than 20 disease-modifying therapies for MS patients. Spinal muscular atrophy, once a devastating and often fatal childhood disease, has been transformed by gene-based therapies. Genetic sequencing has changed the diagnosis and treatment of diseases such as Duchenne muscular dystrophy. And Alzheimer's disease is now entering a period of unprecedented biological understanding and therapeutic development.

Underlying this leap is the discovery and application of blood-based biomarkers that give us an opportunity to identify disease earlier, understand which biological processes are active in an individual patient, monitor disease over time, and determine whether a treatment is working. Ultimately, blood-based biomarkers hold the potential to move neurology toward a more precise, biology-driven approach to diagnosis and treatment.

From diagnosing disease to understanding disease

Biomarkers are not new to neurology. For MS, oligoclonal bands have been an important diagnostic tool for more than 70 years. What has changed is our ability to identify biomarkers that reflect underlying disease activity, tissue injury, and treatment response.

For conditions like progressive MS and Alzheimer's disease, neurofilament light chain, or NfL, is a good example. NfL is a marker of neuronal and axonal injury likely elevated in MS and Alzheimer’s patients. In MS specifically, changes in NfL can provide information about disease activity and neuronal injury, sometimes complementing what we see clinically or on MRI. GFAP, or glial fibrillary acidic protein, provides another window into the nervous system by reflecting astrocytic activation and gliosis. Likewise, phosphorylated tau, particularly p-tau217, has become an important component of Alzheimer's disease biomarker research.

As we discover the power of these biomarkers, we are learning important lessons. For example,  biomarkers are rarely completely disease-specific. P-tau181, for example, can also be elevated in patients with amyotrophic lateral sclerosis (ALS), while p-tau217 may rise in other neurodegenerative conditions and following cerebrovascular injury. The complexity of biomarker discovery is not a weakness of the field. It is a reminder that neurological disease is biologically multi-faceted. Our challenge is to understand what each biomarker is telling us and, increasingly, how multiple biomarkers can be interpreted together.

Alzheimer's disease shows why earlier detection matters

Alzheimer's disease illustrates the potential of blood-based biomarkers particularly well. By the time cognitive symptoms become apparent in an individual, amyloid pathology may have been accumulating in the brain for 15 to 20 years.

Historically, confirming the presence of amyloid required either PET imaging or cerebrospinal fluid analysis. Both have tremendous clinical value, but neither is ideal for large-scale screening or repeated monitoring. MRI can identify structural changes such as hippocampal and cortical atrophy, but those changes generally occur relatively late in the disease process. Amyloid PET can identify amyloid accumulation years before symptoms appear, but it is expensive, involves radiation exposure, and does not tell us how quickly an individual patient's disease will progress.

Collecting a blood specimen is fundamentally different, and game-changing. Blood-based biomarkers are minimally invasive, relatively inexpensive, and potentially scalable across large populations. They can be repeated over time, creating the possibility of monitoring disease biology almost in real time. Most importantly, biomarkers such as p-tau, NfL, and GFAP may provide evidence of underlying neurological changes before major structural abnormalities become apparent on conventional imaging.

In this way, blood-based biomarkers offer something we neurologists have longed for: an opportunity to identify disease earlier, when there may still be time to intervene.

Biomarkers could transform clinical trials

Earlier biological detection also has enormous implications for research. Some of the earliest Alzheimer's clinical trials were conducted without reliable ways to confirm whether participants actually had Alzheimer's pathology. Patients with different causes of cognitive impairment could therefore be enrolled in the same study. That biological heterogeneity makes it much harder to determine whether a treatment is truly effective.

Today, blood biomarkers can complement cerebrospinal fluid analysis and imaging to identify appropriate patients with greater diagnostic certainty. This has the potential to make clinical trials more efficient. Investigators can enrich studies with participants who are most likely to have the biological process the treatment is designed to target. That can reduce heterogeneity, potentially decrease screen failures, and increase confidence that trial results reflect the effect of the intervention rather than differences in underlying disease.

The same principle applies to treatment monitoring. In MS, for example, highly effective therapies can suppress inflammatory disease activity, causing NfL levels to shift toward normal as neuronal injury decreases. A biomarker can therefore provide objective evidence of what is happening biologically, even before changes are detected through conventional measures.

Context matters

As enthusiastic as I am about blood-based biomarkers, I believe we need to be thoughtful about how we use them. No laboratory test should be interpreted in isolation. Sensitivity and specificity are important, but so are pretest probability and disease prevalence. These factors ultimately determine the positive and negative predictive value of a test.

Consider a blood test designed to identify sporadic, late-onset Alzheimer's disease. If we administer that test indiscriminately to healthy college students, almost every result will be negative. That doesn't mean the test is inadequate. It means we are testing a population in which the disease biology we are looking for is uncommon. The same principle applies to age and disease phenotype. Biomarkers optimized for late-onset Alzheimer's disease may be less informative in someone with early-onset disease, where genetic testing and other approaches may be more appropriate.

This is why I believe the future is not about replacing clinical judgment with laboratory testing. It is about combining clinical information, imaging, genetics, and biomarkers to produce a more complete understanding of each patient.

The next frontier: multiple biomarkers

One of the most interesting developments ahead is the move toward multi-analyte biomarker panels. Neurodegenerative disease is rarely caused by a single pathological process. Autopsy studies have shown that Alzheimer's pathology can coexist with conditions such as Lewy body disease. If we measure only one biological pathway, we may miss important contributors to an individual's disease. Therefore, future panels may simultaneously assess amyloid, tau, synuclein, neuroaxonal injury, glial activation, and other biological processes.

Multi-analyte panels would represent a significant conceptual shift in neurology. Instead of simply asking, "Does this patient have Alzheimer's disease?" we could begin asking, "What biological processes are contributing to this patient's neurological disease?" That is a much more powerful question.

Making precision neurology accessible

The ultimate goal of developing increasingly sophisticated testing is to make precision diagnostics faster, more accessible, and more affordable. Today, advanced imaging and genetic testing can provide extraordinary information, but access remains uneven and costs can be substantial. Blood-based biomarkers could add another tool that is easier to deploy across different healthcare settings.

Similarly, biomarkers could also change how we conduct research. Decentralized clinical trials and mobile phlebotomy can reduce the need for patients to repeatedly travel to academic medical centers. By allowing blood samples to be collected at community laboratories or in a patient's home, we can potentially improve recruitment and retention while expanding participation to rural, medically underserved, and geographically distant populations.

In the end, healthcare accessibility is essential. Scientific advances only have an impact if patients can benefit from them.

Looking ahead

When I look at how far neurology has come during my career, I am remarkably optimistic.

While blood-based biomarkers have been an important part of that transformation, I don't see them as replacing MRI, PET, cerebrospinal fluid analysis, genetic testing, or the neurological examination. Rather, they give us another lens through which to understand disease—and potentially a much more accessible one.

Neurology has spent decades learning how to recognize disease. We are now beginning to learn how to measure it. That shift—from symptoms to biology, from diagnosis to prediction, and ultimately from reaction to prevention—could fundamentally change the way we understand and treat neurological disease. That enables physicians to go beyond diagnosing neurological disease after damage has occurred. The time has come to identify biological changes early enough to prevent or slow irreversible injury.